HOLYOKE MEDICAL CENTER
1. Target Overview & Investment Thesis
HOLYOKE MEDICAL CENTER is a 201-bed under-performing / distressed in HAMPDEN, MA with $176.9M in net patient revenue and a -17.8% operating margin. The hospital serves a payer mix of 29.4% Medicare, 10.7% Medicaid, and 59.9% commercial.
Thesis: Undervalued. Our ML models identify $13.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -17.8% to -10.4% (+736bps).
| Net Revenue HCRIS | $176.9M |
| Current EBITDA COMPUTED | $-31.4M |
| Operating Margin COMPUTED | -17.8% |
| Occupancy HCRIS | 47.1% |
| Revenue / Bed COMPUTED | $880K |
| Net-to-Gross HCRIS | 33.3% |
| Distress Probability ML | 51.7% |
2. Market Context & Competitive Position
MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -17.8% places it below the state median. Among 55 size-comparable peers (100-402 beds), the median margin is -10.1%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (100-402), prioritizing same-state peers. 55 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| HOLYOKE MEDICAL CENTER (Target) | MA | 201 | $176.9M | -17.8% |
| LAHEY CLINIC HOSPITAL INC. | MA | 345 | $991.1M | -4.2% |
| TUFTS MEDICAL CENTER | MA | 385 | $819.5M | -49.1% |
| SOUTH SHORE HOSPITAL | MA | 374 | $711.6M | -12.0% |
| NEWTON WELLESLEY HOSPITAL | MA | 216 | $624.3M | -4.7% |
| CAPE COD HOSPITAL | MA | 239 | $620.3M | -1.3% |
| BERKSHIRE MEDICAL CENTER | MA | 238 | $522.9M | -12.9% |
| NORTH SHORE MEDICAL CENTER | MA | 268 | $503.5M | -12.9% |
| LOWELL GENERAL HOSPITAL | MA | 390 | $456.0M | -29.1% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $13.0M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $3.7M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $3.5M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $3.5M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $2.2M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $113K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-31.4M |
| + RCM Uplift | +$13.0M |
| Pro Forma EBITDA | $-18.4M |
| Current Margin | -17.8% |
| Pro Forma Margin | -10.4% |
| WC Released (1x) | $6.8M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-48.4M | $-77.2M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-48.4M | $-100.6M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-43.5M | $-73.3M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-43.5M | $-92.9M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-53.2M | $-126.6M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-53.2M | $-156.5M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| High | Elevated distress probability | Model estimates 51.7% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 55 hospitals with 100-402 beds
- Same-state prioritization (n=56)
- Comp margins: P25=-27.6% / P50=-10.1% / P75=0.2%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.